Hutchmed (China) Limited is a commercial-stage biopharmaceutical company engaged in the research, development, manufacture, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates a fully integrated platform that spans discovery, development, manufacturing, and commercialization. Its business segments include the provision of professional scientific and technical support services, as well as sales, distribution, and marketing services to pharmaceutical manufacturers. Hutchmed manufactures and distributes healthcare products, including prescription drugs and consumer health products, in China. The company maintains GMP-standard manufacturing facilities in Suzhou and Shanghai, China, and has qualified drug product sites in Switzerland to support global supply. It serves markets in China, the United States, the European Union, and Japan. Notable products include FRUZAQLA (fruquintinib), ATLED (fanregratinib), and ORPATHYS (savolitinib). The company has established a licensing agreement with GSK for the KRAS-EGFR antibody-targeted therapy conjugate HMPL-A830. Hutchmed has operated in the pharmaceutical sector for over two decades.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage hutch-med.com
Sector Healthcare IR page hutch-med.com
Tags
oncology, immunology, targeted therapies, immunotherapies, cancer treatment, drug discovery, clinical trials, pharmaceutical manufacturing, biopharmaceuticals, precision medicine, FRUZAQLA, fruquintinib, ATLED, fanregratinib, ORPATHYS, savolitinib, TAGRISSO, HMPL-A830, SANOVO, SAFFRON, SACHI, FRESCO-2, ESLIM-01, Sovleplenib
Press page hutch-med.com/news

Metrics

Valuation  
Market cap HK$ 18.73B
Market cap (USD) $ 2.387B
P/E 5.18
PEG —
P/BV 1.91
P/S 4.35
P/OCF -36.92
P/FCF —
Dividend yield —
Turnover / mcap 0.41%
Returns  
ROE 371.5%
ROI 483.3%
ROIC 483.3%
Profit margin 83.4%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 12.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 548.512M 630.201M 837.999M 426.409M 356.128M 227.976M — — —
Net profit 457.732M 38.17M 101.094M -360.386M -167.041M -115.517M — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price — 3.43 3.98 3.49 7.32 — — — —
Price performance 12m — -0.14 0.14 -0.52 — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Hutchmed (China) Limited (ticker 13), listed in Hong Kong.

ETFs Holding Hutchmed (China) Limited

ETF Weight in ETF Shares Market value As of
AVEE 0.19% 85,500 $ 250.503K Nov 16, 2026
DFSE 0.02% 28,312 $ 100.848K Nov 12, 2026
DFEM 0.02% 457,074 $ 1.443M Nov 12, 2026
DFAX 0.01% 219,110 $ 685.267K Nov 12, 2026
AVEM 0.00% 317,500 $ 930.23K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
HCM Common share — US nasdaq 14.63 USD 2026-09-30
HCM Common share — GB lse — —
13 canonical Common share — HK hkex 21.48 HKD 2026-11-19